This study provides important evidence on the efficacy and safety of GLP-1-based agents in a Chinese population and supports the potential of mazdutide as a potent GLP-1 and glucagon dual agonist for the treatment of overweight and obesity. The gene discussed is GLP1R; the disease is Obesity.